Key facts
- This page summarizes Robert Benjamin Stein's Form 4 filing for Protagenic Therapeutics, Inc.\new (PTIX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Mar 2024, 21:29.
Robert Benjamin Stein - 25 Mar 2024 Form 4 Insider Report for Protagenic Therapeutics, Inc.\new (PTIX)
- Reporting relationship
- Director
- Issuer ticker
- PTIX
- Reported as of
- 25 Mar 2024
- Net transaction value
- +$130,500
- SEC form
- 4
- Accepted by SEC
- 29 Mar 2024, 21:29:23 UTC
- Prior SEC filing
- 17 May 2023
- Next SEC filing
- 06 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ William F. Hulse as attorney in fact for Robert Benjamin Stein
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Benjamin Stein filed Form 4 for Protagenic Therapeutics, Inc.\new (PTIX) on 29 Mar 2024.
Change
- Previous filing in this sequence was filed on 17 May 2023.
- Current net transaction value: +$130,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PTIX
transaction
Derivative
PTIX Common stock Options
Award
- Transaction value
- $130,500
- Shares
- +75,000
- Change %
- Price
- $1.74
- Shares after
- 75,000
- Date
- 25 Mar 2024
- Ownership
- Direct
- Underlying class
- PTIX Common Stock, Par Value $0.0001
- Underlying amount
- 75,000
- Exercise price
- $1.74
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
50,000 of the options are fully-exerciseable on March 25, 2026. The other 25,000 of the options are exercisable on and after the date upon which the company consummates a corporate partnership, if that occurs before December 31, 2026. If the company does not enter into a corporate partnership before December 31, 2026, then those 25,000 options are never exercisable.